Lung Cancer | Specialty

The Continuum of Care in NSCLC

May 25th 2018

NSCLC Patients and Education About Therapy

May 25th 2018

Communicating With the NSCLC Patient

May 25th 2018

Precision Medicine for NSCLC and the Role of APPs

May 25th 2018

Importance of Tumor Boards in NSCLC Management

May 25th 2018

How Much Tissue Do You Need for NSCLC Diagnosis?

May 25th 2018

Pathologist Role in Tissue Acquisition for NSCLC Diagnosis

May 25th 2018

Optimal Multidisciplinary Teamwork in NSCLC

May 25th 2018

Dr. Urbanic on the Evolution of Radiation in NSCLC

May 25th 2018

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.

Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC

May 24th 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).

Ramalingam Weaves Through Expanding SCLC Landscape

May 23rd 2018

Suresh S. Ramalingam, MD, sheds light on the recent data with emerging agents in small cell lung cancer.

Dr. Gold on the Future of Osimertinib in Lung Cancer

May 22nd 2018

Kathryn A. Gold, MD, associate professor of medicine, University of California, San Diego, discusses the future of osimertinib (Tagrisso) in the treatment of patients with EGFR-mutant lung cancer.

A Whirlwind of Change in Lung Cancer

May 22nd 2018

Novel combination regimens anchored by pembrolizumab (Keytruda), atezolizumab (Tecentriq), or nivolumab (Opdivo) are opening the door to new options and an opportunity to personalize therapy in non–small cell lung cancer.

Expert Panel Says Evidence Does Not Yet Support Most ctDNA Testing Outside of Clinical Trials

May 18th 2018

There is very little evidence of clinical validity or clinical utility to justify the widespread use of circulating tumor DNA assays in most patients with advanced cancer, according to a panel of experts from ASCO and the College of American Pathologists

To Radiation With Love: A Bench-to-Bedside Immunotherapy Story

May 18th 2018

Investigators from Montefiore developed a novel combination that has now demonstrated early-stage efficacy in metastatic lung cancer.

Dr. Besse on Combination of Necitumumab and Abemaciclib in NSCLC

May 17th 2018

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of necitumumab (Portrazza) and abemaciclib (Verzenio) in patients with stage IV non–small cell lung cancer.

NGS Established as Most Cost-Effective Genetic Test for Metastatic NSCLC

May 17th 2018

Next-generation sequencing in metastatic non-small cell lung cancer can save Center for Medicare and Medicaid Services payers $1.4 million to $2.1 million.

FTase Inhibition Holds Promise for RAS Targeting and Beyond

May 16th 2018

Although mutant RAS has proved to be a challenging therapeutic target, recent success with tipifarnib, a biologically active drug known as a farnesyltransferase inhibitor, brings promise for treating solid tumors and hematological malignancies.

Leading ALK Researcher Tackles Resistance Challenge in NSCLC

May 15th 2018

Alice T. Shaw, MD, PhD, discusses the challenge of resistance mechanisms in the treatment of patients with non–small cell lung cancer whose tumors harbor ALK rearrangements.

Inaugural Guidelines for Patients With HIV Aim to Expand Therapy Options

May 12th 2018

Specific guidance in the HIV-infected population was not previously available, partly because persons living with HIV were previously excluded from cancer clinical trials, creating a knowledge gap.